HESKA CORP
HESKA CORP (HSKA): 2 pipeline candidates · ~52 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
52.1 months
D/E 0.42
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for HESKA CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$125.2M
Quarterly Burn
$9.2M
Runway
52.1 mo
Revenue
$62.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| nu.q | Preclinical |
| tri-heart plus chewable | Approved |
Frequently asked questions
How many drug candidates are in HESKA CORP's pipeline?
HESKA CORP (HSKA) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HESKA CORP's lead drug candidate?
HESKA CORP's most advanced tracked candidate is nu.q (Preclinical) for cancer screening and monitoring for dogs and cats.
What is HESKA CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, HESKA CORP has approximately 52.1 months of cash runway.
Who is the CEO of HESKA CORP?
Scott W. Humphrey is the chief executive officer of HESKA CORP (HSKA).
Get the full picture on HESKA CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.